Media headlines about MacroGenics (NASDAQ:MGNX) have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. MacroGenics earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.3322809223968 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
MGNX has been the subject of several recent analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and issued a $34.00 price objective on shares of MacroGenics in a report on Tuesday, September 12th. Cowen and Company reaffirmed a “buy” rating on shares of MacroGenics in a report on Friday, August 4th. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $26.00 target price on shares of MacroGenics in a research report on Friday, September 1st. Morgan Stanley dropped their target price on shares of MacroGenics from $22.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Monday, August 7th. Finally, Zacks Investment Research lowered shares of MacroGenics from a “buy” rating to a “hold” rating in a research report on Thursday, August 3rd. Three analysts have rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. MacroGenics has an average rating of “Hold” and a consensus target price of $30.30.
Shares of MacroGenics (MGNX) traded up 2.25% during midday trading on Friday, reaching $19.11. 176,387 shares of the company traded hands. MacroGenics has a 12 month low of $14.36 and a 12 month high of $31.85. The company’s 50 day moving average is $17.66 and its 200-day moving average is $18.14. The stock’s market capitalization is $703.21 million.
MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.09). The company had revenue of $1.70 million for the quarter, compared to analyst estimates of $15.82 million. MacroGenics had a negative return on equity of 56.81% and a negative net margin of 1,216.51%. The business’s revenue was down 97.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.12 earnings per share. Equities research analysts forecast that MacroGenics will post ($4.41) earnings per share for the current fiscal year.
In other MacroGenics news, SVP Jon Marc Wigginton sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, October 25th. The stock was sold at an average price of $20.00, for a total transaction of $200,000.00. Following the transaction, the senior vice president now owns 40,000 shares in the company, valued at $800,000. The sale was disclosed in a document filed with the SEC, which is available through this link. 8.30% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/27/macrogenics-mgnx-receives-daily-media-impact-score-of-0-10.html.
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.